BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 25, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NovoTTF-100L: Phase II data

An open-label, Swiss Phase II trial in 42 patients with locally advanced and metastatic NSCLC showed that NovoTTF-100L in combination with Alimta pemetrexed led to a median overall survival (OS) of 13.8 months vs. a historical OS of 8.3 months for Alimta alone. Median progression-free survival (PFS)...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >